Two-Day Molecular Pathology Diagnostics Symposium ECP 2019 · Nice

e Monday, 9 September 2019 005 09:18 – 09:30 Exploitation of cfDNA extracted from bile as liquid biopsy source in pancreatobiliary MD-01 2-Day MD Symposium cancers 08:30 – 09:30 Clio Caroline Driescher, Germany Selected Abstracts K. Ebner, W. Goering, L. Haeberle, V. Keitel, Chairs: Cristina Teixeido, Spain D. Haeussinger, I. Esposito Bastiaan Tops, The Netherlands MD-02 2-Day MD Symposium 001 08:30 – 08:42 10:30 – 12:00 Clio Plasma cfDNA testing of patients with EGFR Preanalytics mutant non-small cell lung cancer: Chairs: Frederick Klauschen, Germany droplet-digital PCR versus next-generation Erik Jan Dubbink, The Netherlands

Monday, 9 Sept sequencing compared to tissue-based results 001 10:30 – 11:00 Hendrikus Jan Dubbink, The Netherlandss Where a reliable biomarker is born: a new P. N. Atmodimedjo, E. de Jonge, M. Paats, pathology preanalytics in XXIst century C. van der Leest, E. Oomen - de Hoop, Antonio Martinez, Spain J. von der Thüsen, W. Dinjens, R. H. van Schaik, J. Aerts, C. M. J. Steendam 002 11:00 – 11:30 Parallel sequencing after cell separation 002 08:42 – 08:54 from FFPE material Circulating Cell-free DNA in archived low Janna Siemanowski, Germany quality volume serum samples: Rate of (supported by Miltenyi Biotec) concordance with mutation in tumour Behnoush Abedi-Ardekani, France 003 11:30 – 12:00 D. Nasrollahzadeh, T. Delhomme, Suitability of cytological specimen for NGS P. H. Avogbe, M. Foll, J. McKay, P. Brennan, testing R. Malekzadeh Giancarlo Troncone, Italy 003 08:54 – 09:06 Global delivery of external quality MD-03 2-Day MD Symposium assessment for lung cancer liquid biopsy 14:45 – 16:45 Clio testing Quality assurance and guidelines in Zandra Deans, United Kingdom molecular pathology J. Fairley, M. Cheetham, M. Denis, Chairs: Nicola Normanno, Italy E. Dequeker, C. Keppens, F. Fenizia, Etienne Rouleau, France N. Normanno, S. Patton, E. Rouleau, E. Schuuring, K. van Casteren 001 14:45 – 15:09 ESP EQAs: impact on quality improvement 004 09:06 – 09:18 Aleš Ryška, Czech Republic Reflex tumour BRCA1/2 testing in ovarian carcinomas to stratify PARP inhibitor 002 15:09 – 15:33 treatment and germline diagnostics IQN PATH: ring trial on TMB testing Marjolijn Ligtenberg, The Netherlands Francesca Fenizia, Italy J. R. Vos, I. E. Fakkert, J. A. de Hullu, 003 15:33 – 15:39 A. M. van Altena, A. S. Sie, H. Ouchene, IQN PATH: ring trial on liquid biopsy R. W. Willems, I. Nagtegaal, – introduction of trial concept M. C. Jongmans, A. R. Mensenkamp, Jennifer Fairley, United Kingdom G. H. Woldringh, J. Bulten, E. M. Leter, C. M. Kets, M. Simons, N. Hoogerbrugge 004 15:39 – 15:57 IQN PATH: ring trial on liquid biopsy – results from the ESP-EQA Kaat van Casteren, Belgium

70 ECP 2019 · Nice Two-Day Molecular Pathology Diagnostics Symposium

005 15:57 – 16:21 e Tuesday, 10 September 2019 UK NEQAS: NGS, variant nomenclature and reporting Jennifer Fairley, United Kingdom MD-05 2-Day MD Symposium 08:30 – 09:30 Clio 006 16:21 – 16:45 Selected Abstracts French quality assurance programme Chairs: Sabine Merkelbach-Bruse, Germany Gen&tiss Etienne Rouleau, France Karen Leroy, France 001 08:30 – 08:42 MD-04 2-Day MD Symposium Differentially expressed immune related 17:15 – 19:15 Clio genes in metastatic vs. non-metastatic NGS – beyond mutation testing LUMA, LUMB1 and TNBC primary breast Chairs: Marjolijn Ligtenberg, The carcinoma cases Netherlands Anna Maria Tokes, Hungary Sabine Merkelbach-Bruse, Germany O. Rusz, C. Pollner-Szundi, L. Madaras, A. Kovács, B. Molnár, I. Vári-Kakas, J. Kulka 001 17:15 – 17:45 002 08:42 – 08:54 AMP guidelines for variant reporting

Tumour mutational burden analysis: 9 Sept Monday, Marilyn Li, USA implementation in routine diagnostics Planned jointly with AMP Leonie Kroeze, The Netherlands 002 17:45 – 18:15 E. Kamping, D. von Rhein, E. Jansen, CNV detection from NGS data R. de Voer, M. Barberis, J. Botling, Astrid Eijkelenboom, The Netherlands E. Garrido-Martin, F. Haller, L. Lacroix, B. Maes, S. Merkelbach-Bruse, V. Pestinger, 003 18:15 – 18:45 N. Pfarr, A. Stenzinger, K. Grünberg, Fusion gene detection using RNAseq M. Ligtenberg Bastiaan Tops, The Netherlands 003 08:54 – 09:06 004 18:45 – 19:15 Role of HR23b in response to HDAC

Moving beyond DNA sequence: inhibitors and their effect on immunothera- 10 Sept Tuesday, genome-wide profiling of plasma DNA py targets Samantha Perakis, Austria Svenja Wagener-Ryczek, Germany C. Alidousty, C. Heydt, J. Fassunke, S. Merkelbach-Bruse, R. Buettner, M. A. Ihle

004 09:06 – 09:18 MET exon 14 skipping mutations in non small cell lung cancer: efficient routine diagnostics, histopathology and clinical response upon targeted treatment Willemina Geurts-Giele, The Netherlands M. Pruis, J. von der Thüsen, I. Meijssen, W. Dinjens, J. Aerts, M. Lolkema, M. Paats, H. J. Dubbink

005 09:18 – 09:30 The diagnostic landscape and yield of predictive somatic molecular analyses for stratification of cancer therapy in The Netherlands Elisabeth Steeghs, The Netherlands E. K. de Jong, R. W. Willems, Q. J. Voorham, P. A. Seegers, K. Grünberg, M. Ligtenberg

71 Two-Day Symposium for Molecular Biologists ECP 2019 · Nice

MD-06 2-Day MD Symposium MD-08 2-Day MD Symposium 10:30 – 12:00 Clio 17:15 – 19:15 Clio Mutational signatures and bioinformatics New technologies Chairs: Frederick Klauschen, Germany Chairs: Erik Jan Dubbink, The Netherlands Bastiaan Tops, The Netherlands Carina Heydt, Germany

001 10:30 – 11:00 001 17:15 – 17:45 Signal: the homepage of mutational Gene fusions in melanoma and / or skin signatures Arnaud de la Fouchardière, France Jan Czarnecki, United Kingdom 002 17:45 – 18:15 002 11:00 – 11:30 NanoString transcript analysis for the A new user-friendly web application to detection of gene fusion events implement mutational signatures analysis Leon van Kempen, The Netherlands Marcos Diaz-Gay, Spain 003 18:15 – 18:45 003 11:30 – 12:00 Proteogenomic tumour profiling Multiregion human bladder cancer Frederick Klauschen, Germany sequencing reveals tumour evolution, 004 18:45 – 19:15 bladder cancer phenotypes and implications Methylation analysis – a new approach to for targeted therapy sarcoma classification Nadine Gaisa, Germany Andreas von Deimling, Germany

MD-07 2-Day MD Symposium Tuesday, 10 Sept 14:45 – 16:45 Clio Immunooncology Chairs: Marjolijn Ligtenberg, The Netherlands Cristina Teixido, Spain

001 14:45 – 15:15 Multiplexed immunohistochemistry: from translational research to daily practice, is it realistic? Paul Hofman, France

002 15:15 – 15:40 TMB and mutation testing by TSO500 and FoundationOneCDx in NSCLC Johan Botling, Sweden (supported by Illumina)

003 15:40 – 16:05 Comparison of TMB testing by Oncomine TML and FMI Carina Heydt, Germany (supported by ThermoFisher)

004 16:05 – 16:15 Discussion of talk 002 and 003

005 16:15 – 16:45 Molecular residual disease in early-stage NSCLC: lung TRACERx experience Chris Abosh, United Kingdom (supported by BMS)

72 ECP 2019 · Nice Two-Day Symposium for Molecular Biologists e Monday, 9 September 2019 / 007 Pathohistological characteristics of breast e Tuesday, 10 September 2019 cancer in BRCA-positive and BRCA-nega- tive women PS-MD-01 2-Day MD Symposium Snjezana Ramic, Croatia 09:30 – 10:30 Agora 3 I. Kirac, T. Oresic, T. Zigman, V. Musani, Poster Session P. Ozretic, O. Vugrek, I. Milas Chair: Sabine Merkelbach-Bruse, Germany 008 Comparison of four microsatellite instability 001 testing methods in endometrial cancer Expression of transient receptor potential – reliability, handling, cost effectiveness Vanilloid-1 in gliomas vs medulloblastomas Janna Siemanowski, Germany Martha Assimakopoulou, Greece B. Schömig-Markiefka, W. Dietmaier, N. Arens, A. Moutafidi, V. Zolota, G. Gatzounis T. Buhl, R. Büttner, S. Merkelbach-Bruse 002 009 Validation of a novel approach for Association between KRAS, NRAS, BRAF molecular breast cancer classification mutation status and clinicopathological Shawn Baldacchino, Malta prognostic factors in colorectal carcinoma

J. Debattista, C. Saliba, C. Scerri, G. Grech 9 Sept Monday, in Turkish population 003 Duygu Unal Kocabey, Turkey Characterisation of genetic mutation spectra E. Cakir, F.H. Dilek, B. Bolat Kucukzeybek, and identification of gene amplification and A. Calli fusion variants in cell-free nucleic acid from 010 cultured cancer cell media and liquid biopsy Results of the Belgian ring trial for liquid specimens using Oncomine™ pan-cancer biopsy testing in non-small cell lung cancer cell-free assay show variety in the interpretation of the test Ru Cao, USA result K. Lea, J. Schageman, K. Hanif, Y. Li, J. Gu, Kaat van Casteren, Belgium V. Bagai, P. Kshatriya, A. Luchetti, L. Quagliata,

K. Dufraing, P. Pauwels, N. D’Haene, E. 10 Sept Tuesday, H. Wikman, S. Loges, K. Bramlett Dequeker 004 011 Case report: NGS of cell-free DNA from Establishment of a 3D histopathology blood and bile as a follow-up strategy in platform for precision tumour diagnosis a patient with metastatic pancreatic Jialing Yang, Taiwan adenocarcinoma Y. Lin, A. Chiang, I. Wang, S. Wu, Katharina Ebner, Germany M. D. Chang, J. Lee, J. Ko, S. Liang, J. Guo, C. Driescher, W. Goering, L. Haeberle, X. Song, H. Huang, M. Chao, C. Lin V. Keitel, D. Haeussinger, I. Esposito

005 Effect of radio-wave and molecular resonance surgery on rat neck skin regeneration Igor Kastyro, Russia P. Pryanikov, A. Alsufev, V. Popadyuk, A. Kovalenko, A. Sedelnikova, N. Kamanina

006 Up-converting nanoparticles as a tool for histopathological tissue evaluation with multiplexing and machine learning potential Krzysztof Krawczyk, Sweden S. Andersson-Engels, A. Sjögren 73